著者 後藤田 達洋| 川野 誠司| 河野 吉泰| 三浦 公| 神崎 洋光| 岩室 雅也| 河原 祥朗| 田中 健大| 吉野 正| 白川 靖博| 田端 雅弘| 谷本 光音| 岡田 裕之|
発行日 2016-12-01
出版物タイトル 岡山医学会雑誌
128巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/14775
タイトル(別表記) A case of anti - neutrophil cytoplasmic autoantibody-associated vasculitis: Resolution after early diagnosis
フルテキストURL 73_088_092.pdf
著者 市川 裕久| 芦田 耕三| 小野 勝一郎| 高田 真吾| 横井 正| 永田 拓也| 岡本 誠| 柘野 浩史| 西田 典数| 保﨑 泰弘| 光延 文裕| 谷崎 勝朗| 野口 菩範| 谷本 光音|
抄録 症例は76歳男性03年前肺気腫と診断された。今回呼吸器リハビリテーション目的で当院に入院の運びとなった。入院時より37-38'Cの発熱を認め,下気道感染を疑い抗生剤で加療したが改善しなかった.入院時の検尿検査で蛋白・潜血陽性であり,血清MPO-ANCAが307U/mlと高値を示した。血清クレアチニン値も徐々に上昇してきたため,MPO-ANCA関連血管炎と診断した.プレドニゾロン投与を開始したところ,症状及び検査所見は速やかに改善した.
キーワード ANCA関連血管炎 早期診断 顕微鏡的多発血管炎
出版物タイトル 岡大三朝医療センター研究報告
発行日 2003-02-01
73巻
開始ページ 88
終了ページ 92
ISSN 1348-1258
言語 Japanese
論文のバージョン publisher
NAID 120002308580
JaLCDOI 10.18926/14774
タイトル(別表記) A case of Parkinson's disease associated with bromocriptine - induced leukopenia and throm-bocytopenia
フルテキストURL 73_084_087.pdf
著者 高田 真吾| 御舩 尚史| 光延 文裕| 岡本 誠| 西田 典数| 柘野 浩史| 芦田 耕三| 保崎 泰弘| 横井 正| 谷崎 勝朗| 新谷 憲治| 谷本 光音|
抄録 症例は67歳,女性。以前からパーキンソン病にて加療されていたが,リハビリテーション目的で当院入院した.入院時白血球数,血小板数正常であったが,bromocriptine投与開始後白血球減少,血小板減少を認めた.薬剤性白血球減少症及び血小板減少症を疑い, bromocriptine投与中止するとともにfilgrastim投与により,白血球減少,血小板減少は改善した。誘発試験施行し白血球減少を認めた。Bromocriptineによる白血球減少症,血小板減少症の報告は少なく,我々の検索しえた範円内では本症例を含めて2例のみであった。Bromocriptineには安全性や神経保護作用に関して多くのデータの蓄積があるが,安全性に十分な注意が必要であると考えられた。
キーワード パーキンソン病 (Parkinson's disease) ブロモクリプチン (Bromocriptine) 白球血減少症 (Leukopenia) 血小板減少症 (Thrombocytopenia) フィルグラスチム (Filgrastim)
出版物タイトル 岡大三朝医療センター研究報告
発行日 2003-02-01
73巻
開始ページ 84
終了ページ 87
ISSN 1348-1258
言語 Japanese
論文のバージョン publisher
NAID 120002308217
JaLCDOI 10.18926/14768
タイトル(別表記) 気管支喘息に対する温泉療法とα-リノレン酸強化食の効果
フルテキストURL 73_055_063.pdf
著者 岡本 誠| 芦田 耕三| 光延 文裕| 保崎 泰弘| 柘野 浩史| 西田 典数| 永田 拓也| 横井 正| 高田 真吾| 谷崎 勝朗| 谷本 光音|
抄録 N-3 fatty acids are reportedly effective for asthma. In addition, spa therapy has been reported to be effective for patients with asthma. In the present study, the effects of spa therapy combined with perilla seed oil- rich diet (rich in n-3 fatty acid)were examined on asthma. A total of 14 asthmatic patients had a complex spa therapy and consumed a perilla seed oil- rich diet - rich in a -linolenic acid (alpha-LNA) for 8 weeks. Generation of leukotriene (LT) C4 by leucocytes, respiratory function were analyzed. The generation of LTC4 by leucocytes decreased significantly for 2, 4 and 8 weeks (P<O.05). Peak expiratory flow (PEF) values increased significantly for 2,4, 6 and 8 weeks (P<O.05). The values of ventilatory parameters [forced vital capacity (FVC) , forced expiratory volume in one second (FEV(1)) forced expiratory flow after 25% of expired FVC (FEF(25)), forced expiratory flow after 75% of expired FVC (FEF (75)) • mean expiratory flow during the middle half of the FVC (FEF(25-75)) ] revealed a significant increase after 4 and 8 weeks of the modified diet (P<O.05). The results suggest that spa therapy combined with a perilla seed oil- rich diet are effective in the treatment of asthma in terms of its ability to suppress LTC4 generation by leucocytes, and in inducing an improvement of pulmonary function.
キーワード bronchial asthma spa therapy perilla seed oil alpha -linolenic acid Leukotriene C4
出版物タイトル 岡大三朝医療センター研究報告
発行日 2003-02-01
73巻
開始ページ 55
終了ページ 63
ISSN 1348-1258
言語 English
論文のバージョン publisher
NAID 120002308428
JaLCDOI 10.18926/14750
タイトル(別表記) 気管支喘息の low attenuation are (LAA) に対する長期喫煙の影響-4年間の経過観察-
フルテキストURL 73_010_018.pdf
著者 光延 文裕| 芦田 耕三| 保﨑 泰弘| 柘野 浩史| 岡本 誠| 西田 典数| 永田 拓也| 高田 真吾| 横井 正| 中井 睦郎| 谷崎 勝朗| 谷本 光音|
抄録 Background-The influence of cigarette smoking on the pathogenesis of asthma in the elderly remains controversial. This study attempts to estimate longitudinal changes in HRCT (high resolution computed tomography) parameters and pulmonary function parameters obtained for ex-smokers and never-smokers in asthmatics during 4-yr follow-up period. Methods-Fourteen asthmatics (6 ex-smokers and 8 never-smokers) were studied to determine the influence of aging and cigarette smoking on pulmonary function, and mean lung density (MLD) and the relative area of the lung showing attenuation values less than -950 HU (RA950) on HRCT scans. Results-The values of FVC and FEV1, were significantly more decreased in asthmatics without a smoking history during 4-yr follow-up period. The values of FVC, FEV1, FEV1/FVC and DLco/VA were significantly decreased and RV/TLC were significantly increased in asthmatics with a smoking history over 4 years, and annual decline in FEV1 ex-smokers was larger than that in never-smokers. In the upper lung field, inspiratory MLD was observed to shift in a negative direction and inspiratory RA950 was found to increase during 4-yr observation period in ex-smokers, but not in never-smokers. In the middle lung field, inspiratory RA950 was significantly enhanced in both two groups. Although expiratory MLD, expiratory RA950 and exp RA950/ins RA950 were observed to change significantly during the observation period in ex-smokers, no changes were observed in never-smokers. Conclusion-These results suggest that aging augments airspace enlargement predominantly in the middle lung field, while long term cigarette smoking further worsens emphysematous alterations in the upper lung field.
キーワード lung density high resolution computed tomography asthma
出版物タイトル 岡大三朝医療センター研究報告
発行日 2003-02-01
73巻
開始ページ 10
終了ページ 18
ISSN 1348-1258
言語 English
論文のバージョン publisher
NAID 120002308656
JaLCDOI 10.18926/AMO/54499
フルテキストURL 70_4_243.pdf
著者 Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
抄録 Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
キーワード vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 243
終了ページ 253
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549668
Web of Science KeyUT 000384748600003
JaLCDOI 10.18926/AMO/32866
フルテキストURL fulltext.pdf
著者 Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune|
抄録 <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were &#60;70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p>
キーワード cisplatin docetaxel irinotecan triplet chemotherapy gefitinib
Amo Type Original Article
発行日 2010-02
出版物タイトル Acta Medica Okayama
64巻
1号
出版者 Okayama University Medical School
開始ページ 33
終了ページ 37
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 20200582
Web of Science KeyUT 000274868300005
JaLCDOI 10.18926/AMO/31714
フルテキストURL fulltext.pdf
著者 Kawada, Kazuhiko| Yonei, Toshiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Harada, Mine| Tanimoto, Mitsune|
抄録 <p>When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.</p>
キーワード chemosensitivity test 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltertrazolium bromide (MTT) assay clonogenic assay
Amo Type Article
発行日 2002-06
出版物タイトル Acta Medica Okayama
56巻
3号
出版者 Okayama University Medical School
開始ページ 129
終了ページ 134
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12108583
Web of Science KeyUT 000176521200002
JaLCDOI 10.18926/AMO/31705
フルテキストURL fulltext.pdf
著者 Takata, Ichiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Katayama, Hideki| Takemoto, Mitsuhiro| Hiraki, Yoshio| Harada, Mine| Tanimoto, Mitsune|
抄録 <p>A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC). Patients with inoperable NSCLC who had poor risk factors such as advanced age, poor performance status, poor lung function, or concomitant active malignancy were entered into the study. Low-dose cisplatin (6 mg/m2) was administered daily before concurrent thoracic irradiation (2 Gy/day; total dose of 60 Gy) was given. Twenty-five patients were registered. The majority of the patients had either stage IIIA (24.0%) or stage IIIB (60.0%) disease. Fifteen patients (60.0%) completed the planned treatment. Both chemotherapy and radiotherapy were stopped in 3 patients (12.0%) due to poor response, and 7 patients (28.0%) partly received radiotherapy alone as a result of their toxicity response. The proportion of total administered dose to planned dose was 90.9% for chemotherapy and 99.3% for radiotherapy, which were comparable to those in previous studies for LA-NSCLC patients without poor risk factors. Grade 3 leukopenia and neutropenia developed in 14 patients (56.0%) and 10 patients (40.0%), respectively, but grade 4 toxicity was not encountered. Grade 3 pneumonitis and esophagitis were observed in 4 patients (16.0%) and 2 patients (8.0%), respectively. The overall response rate was 60.0%. The median survival time was 22 months, and the 2-year survival rate was 50.3%. Daily low-dose cisplatin and concurrent thoracic irradiation were well tolerated even by poor-risk patients with NSCLC, and showed a therapeutic efficacy similar to that for good-risk patients.</p>
キーワード non-small-cell lung cancer concurrent chemoradiotherapy low-dose cisplatin poor-risk factor
Amo Type Article
発行日 2002-10
出版物タイトル Acta Medica Okayama
56巻
5号
出版者 Okayama University Medical School
開始ページ 261
終了ページ 266
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12530510
Web of Science KeyUT 000178668100007
JaLCDOI 10.18926/AMO/30751
フルテキストURL fulltext.pdf
著者 Kitajima, Takuji| Nishii, Kenji| Ueoka, Hiroshi| Shibayama, Takuo| Gemba, Kenichi| Kodani, Tsuyoshi| Kiura, Katsuyuki| Tabata, Masahiro| Hotta, Katsuyuki| Tanimoto, Mitsune| Sobue, Tomotaka|
抄録 <p>To evaluate recent improvements in lung cancer screening, we compared the results of recently conducted lung cancer screening with those of a previous screening. This study compared the survival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred seventy-six patients with lung cancer were detected in the early period and 541 patients with lung cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8 months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer detected in the late period were significantly better than those in the early period (p = 0.0054). Among patients undergoing resection, the proportion of pathological stage I patients in the late period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p = 0.005). Multivariate analysis showed that the screening time period was a significant prognostic factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results were consistent with the findings of case-control studies of lung cancer screening programs in the late period recently conducted in Japan, which also showed a greater efficacy for screening than for previous case-control studies in the early period.</p>
キーワード lung cancer screening survival lung cancer mortality
Amo Type Article
発行日 2006-06
出版物タイトル Acta Medica Okayama
60巻
3号
出版者 Okayama University Medical School
開始ページ 173
終了ページ 179
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16838046
Web of Science KeyUT 000238503600005
JaLCDOI 10.18926/AMO/30737
フルテキストURL fulltext.pdf
著者 Suzaki, Noriyuki| Hiraki, Akio| Takigawa, Nagio| Ueoka, Hiroshi| Tanimoto, Yasushi| Kozuki, Toshiyuki| Tabata, Masahiro| Kanehiro, Arihiko| Kiura, Katsuyuki| Tanimoto, Mitsune|
抄録 A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel.
キーワード paclitaxel adverse effect lung cancer interstitial pneumonia
Amo Type Article
発行日 2006-10
出版物タイトル Acta Medica Okayama
60巻
5号
出版者 Okayama University Medical School
開始ページ 295
終了ページ 298
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 17072376
Web of Science KeyUT 000241509000006
著者 Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-03-10
出版物タイトル Experimental Cell Research
322巻
1号
資料タイプ 学術雑誌論文
著者 Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-01
出版物タイトル Lung Cancer
83巻
1号
資料タイプ 学術雑誌論文
著者 Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune|
発行日 2011-10
出版物タイトル Lung Cancer
74巻
1号
資料タイプ 学術雑誌論文
著者 松岡 順治| 猶本 良夫| 田端 雅弘| 白川 靖博| 堀田 勝幸| 谷本 光音| 田中 紀章|
発行日 2009-04-01
出版物タイトル 岡山医学会雑誌
121巻
1号
資料タイプ 学術雑誌論文
著者 木浦 勝行| 谷本 安| 田端 雅弘| 金廣 有彦| 上岡 博| 谷本 光音| 渡邊 都貴子| 草野 展周| 小出 典男|
発行日 2005-05-30
出版物タイトル 岡山医学会雑誌
115巻
1号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/47266
フルテキストURL 65_6_403.pdf
著者 Waseda, Koichi| Tanimoto, Yasushi| Ichiba, Shingo| Miyahara, Nobuaki| Murakami, Toshi| Ochi, Nobuaki| Terado, Michihisa| Nagano, Osamu| Maeda, Yoshinobu| Kanehiro, Arihiko| Ujike, Yoshihito| Tanimoto, Mitsune|
抄録 Bronchiolitis obliterans (BO) is a disease with a poor prognosis, and a key factor that limits long-term survival after allogeneic hematopoietic stem cell transplantation (HSCT). We here report a case of a 31-year woman with acute lymphatic leukemia, which was treated by chemotherapy and HSCT, and consequently developed BO 2 years after HSCT. A non-tuberculous mycobacterial infection occurred and showed gradual exacerbation. She started taking anti-mycobacterial drugs, but lost appetite, felt tired and finally lost consciousness one month after beginning medication. Arterial blood gas revealed marked hypercapnia. Using extracorporeal life support (ECLS), the carbon dioxide concentration was reduced and her consciousness recovered. To our knowledge, this is the first case in which ECLS was successfully used for hypercapnia in a patient with BO.
キーワード extracorporeal life support hypercapnia bronchiolitis obliterans noninvasive positive pressure ventilation
Amo Type Case Report
発行日 2011-12
出版物タイトル Acta Medica Okayama
65巻
6号
出版者 Okayama University Medical School
開始ページ 403
終了ページ 406
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22189481
Web of Science KeyUT 000298516900007
著者 谷口 暁| 宮原 信明| 中原 淳| 高田 三郎| 佐久川 亮| 長野 修| 谷本 安| 金廣 有彦| 木浦 勝行| 氏家 良人| 谷本 光音|
発行日 2011-12-01
出版物タイトル 岡山医学会雑誌
123巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/51868
フルテキストURL 67_5_319.pdf
著者 Murakawa, Kiminaka| Sato, Tomoaki| Maeda, Yoshinobu| Kitamura, Yoshihisa| Tanimoto, Mitsune| Sendo, Toshiaki|
抄録 Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.
キーワード beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation
Amo Type Case Report
発行日 2013-10
出版物タイトル Acta Medica Okayama
67巻
5号
出版者 Okayama University Medical School
開始ページ 319
終了ページ 324
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 24145732
Web of Science KeyUT 000325836100006
著者 曽我 賢彦| Maeda, Yoshinobu| Tanimoto, Mitsune| Ebinuma, Takayuki| Maeda, Hiroshi| Takashiba, Shogo|
発行日 2013-02
出版物タイトル Supportive Care in Cancer
21巻
2号
資料タイプ 学術雑誌論文